Ayobami T Akenroye

16PUBLICATIONS
41CO-AUTHORS
Disease surveillanceGene and molecular therapyMetabolic medicineAllergyChild and adolescent development
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jan 19, 2026
The ratio of circulatory levels of sphingolipids to steroids predicts asthma exacerbations.

Yulu Chen, Pei Zhang, Mengna Huang

|Oct 13, 2025
Patients with Higher Exacerbation Burden and Eosinophil Counts are More Likely to Require Multiple Biologics for Asthma Control.

Alyson N Brown, Tanawin Nopsopon, Ayobami Akenroye

|Aug 06, 2024
Untargeted metabolomic analysis reveals different metabolites associated with response to mepolizumab and omalizumab in asthma.

Tanawin Nopsopon, Yulu Chen, Qingwen Chen

|Apr 18, 2024
Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study.

Ratko Djukanović, Paul Brinkman, Johan Kolmert

|Jan 02, 2024
Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.

Tanawin Nopsopon, Nora A Barrett, Wanda Phipatanakul

|Aug 11, 2018
Prevalence of anaphylaxis among adults admitted to critical care for severe asthma exacerbation.

Ayobami T Akenroye, Abayomi Ajala, Elham Azimi-Nekoo

Pageof 3

Frequent Collaborators

5 joint publications

Philippe Eigenmann

3 joint publications

Craig Wheelock

2 joint publications

Michael McGeachie

2 joint publications

Ömer Kalayci